TipRanks
Climb Bio (CLYM)
NASDAQ:CLYM
US Market
CLYM
Climb Bio
RESEARCH TOOLSreports
Want to see CLYM full AI Analyst Report?

Climb Bio (CLYM) Stock News & Sentiment

738 Followers
Selvaraju Reiterates Buy on Climb Bio, Maintains $30 Price Target on Strong Kidney Pipeline Data
Premium
Ratings
Selvaraju Reiterates Buy on Climb Bio, Maintains $30 Price Target on Strong Kidney Pipeline Data
4d ago
CLYM
Climb Bio Highlights Promising Phase 2 Kidney Trial Data
Premium
Company Announcements
Climb Bio Highlights Promising Phase 2 Kidney Trial Data
5d ago
8K
CLYM
Climb Bio Highlights Promising Phase 1 IgA Therapy Data
Premium
Company Announcements
Climb Bio Highlights Promising Phase 1 IgA Therapy Data
8d ago
8K
CLYM
Matt Phipps Initiates Buy on Climb Bio, Citing Strong Early CLYM116 Data and Support for Once‑Every‑12‑Weeks Dosing Strategy
Premium
Ratings
Matt Phipps Initiates Buy on Climb Bio, Citing Strong Early CLYM116 Data and Support for Once‑Every‑12‑Weeks Dosing Strategy
2M ago
CLYM
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
Premium
Company Announcements
Climb Bio Reports Encouraging Initial Phase 1 CLYM116 Data
2M ago
8K
CLYM
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook
Premium
Ratings
CLYM116’s Differentiated APRIL ‘Sweeper’ Design Sets Up Phase I Data as Key Catalyst for IgA Nephropathy Outlook
2M ago
CLYM
Climb Bio Advances Phase 2 Renal Disease Trial
Premium
Company Announcements
Climb Bio Advances Phase 2 Renal Disease Trial
3M ago
8K
CLYM
More CLYM News >

CLYM News on the Web

Climb Bio announces new data for budoprutug
TipRanks News
Bullish
BTIG Reaffirms Their Buy Rating on Climb Bio (CLYM)
TipRanks News
Bullish
Climb Bio added to ‘Analysts Current Favorites’ at Raymond James
TipRanks News
Bullish
Director Stephen Thomas Sells 100,000 Shares of Climb Bio Inc (CLYM)
GuruFocus News
Neutral
Climb Bio management to meet with Piper Sandler
TipRanks News
Bullish
Climb Bio Advances Phase 2 Renal Disease Trial
TipRanks News
Neutral
Truist Financial Sticks to Their Buy Rating for Climb Bio (CLYM)
TipRanks News
Bullish
Is Climb Bio Inc (CLYM) Making Progress Despite Q2 Loss? EPS: -$0.18, GF Score: 22/100
GuruFocus News
Bearish

News Score - Last 7 Days

Very Positive
CLYM
Sector Average
Media Buzz
This Week9 articles
Weekly Average2.25 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CLYM’s Media Buzz Sentiment?
9 articles about CLYM were published this week. In an average week, 2.25 articles are published.
    What is CLYM’s weekly average amount of articles?
    In an average week, 2.25 articles about CLYM are published.
      What is CLYM’s News Sentiment?
      100% of articles about CLYM were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        CNCCentene
        GMABGenmab
        LHLabcorp Holdings
        KIDSOrthoPediatrics
        DXCMDexcom
        Showing the stocks with the most bullish news sentiment over the past week